In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025

In situハイブリダイゼーション(ISH)の世界市場予測(〜2025):製品別(消耗品(キット、プローブ)、ソフトウェア)、技術別(FISH(DNA、RNA)、CISH)、用途別(癌、感染症)、エンドユーザー別(診断ラボ、研究所、CRO)、地域別

◆タイトル:In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025
◆商品コード:BT 3649
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年8月18日
◆ページ数:162
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:バイオ
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

Marketsandmarkets社はIn situハイブリダイゼーション(ISH)の世界市場が2020年9億ドルから2025年13億ドルまで、年平均7.4%成長すると予測しています。本調査レポートでは、In situハイブリダイゼーション(ISH)の世界市場を調査・分析することで、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、製品別(消耗品、楽器、ソフトウェア)分析、技術別(FISH、CISH)分析、用途別(癌、細胞診断、感染症、神経科学、免疫)分析、エンドユーザー別(病院・診断研究所、学術研究機関、製薬・バイオテクノロジー企業、契約研究組織)分析、地域別分析、競争状況、企業評価マトリックス及び企業情報など、今後の市場展望をまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・In situハイブリダイゼーション(ISH)の世界市場規模:製品別(消耗品、楽器、ソフトウェア)
・In situハイブリダイゼーション(ISH)の世界市場規模:技術別(FISH、CISH)
・In situハイブリダイゼーション(ISH)の世界市場規模:用途別(癌、細胞診断、感染症、神経科学、免疫)
・In situハイブリダイゼーション(ISH)の世界市場規模:エンドユーザー別(病院・診断研究所、学術研究機関、製薬・バイオテクノロジー企業、契約研究組織)
・In situハイブリダイゼーション(ISH)の世界市場規模:地域別
・競争状況
・企業評価マトリックス及び企業情報

“Increasing incidence of genetic disorders and ISH based companion diagnostics tests are set to drive the ISH market.”
The global in situ hybridization (ISH) market size is projected to reach USD 1.3 billion by 2025 from USD 0.9 billion in 2020, at a CAGR of 7.4% during the forecast period. The increasing incidence of cancer and awareness of companion diagnostics test are the major factors driving the growth of this market. However, the lack of skilled professionals poses a challenge to ISH market.

“By consumables type, the kits & reagents accounted for the fastest-growing segment of the ISH market.”
The kits & reagents segment accounted for the largest share of this market in 2019. The rise in government and private funding in life sciences and cancer research, the increasing number of reagent rental agreements, and the application of innovative technologies and methodologies in the fields of tissue and in vitro diagnostics are expected to drive the growth of the ISH consumables market during the forecast period.

“By technology type, the FISH segment accounted for the largest share of the ISH market.”
Based on technology, the ISH market is segmented broadly into fluorescence in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). This segment accounted for the largest share of the global ISH market in 2019. The large share of this segment is attributed to the increasing demand for FISH kits and assays in CDx for cancer diagnostics, chromosomal abnormalities, and infectious diseases.

“Asia Pacific: The fastest-growing region in the ISH market.”
The Asia Pacific market is projected to grow at the highest CAGR during the forecast period, The economic growth in the countries of this region, its large population base, the rising prevalence of chronic diseases, improvements in the standard of living, growing demand for quality medical care, increasing healthcare spending, government initiatives, and awareness regarding the use of tissue diagnostic tests (including ISH) are the major factors driving market growth in the APAC

“North America: the largest share of the ISH market.”
North America accounted for the largest share of the ISH market. The large share of this segment can primarily be attributed to the presence of major players operating in the ISH market in the US, rising incidence of cancer and infectious diseases, and the increasing adoption of companion diagnostic assay kits.

Breakdown of primaries
The study contains insights from various industry experts, ranging from component suppliers to Tier 1 companies and OEMs. The break-up of the primaries is as follows:

• By Respondent– Supply Side- 80%, Demand Side-20%
• By Designation— Executives- 25%, CXOs- 20%, Managers – 55%
• By Region— North America – 50%, Europe – 20%, APAC – 20%, RoW- 10%

The ISH market is dominated by a few globally established players such as Abbott Laboratories(US), F. Hoffmann-La Roche (Switzerland), Agilent Technologies (US), Danaher Corporation (US), and Thermo Fisher Scientific (US), Abnova Corporation (Taiwan), BioGenex Laboratories (US), Genemed Biotechnologies (US), Bio-techne Corporation (US), Biocare Medical (US), and Bio SB (US), Bio-Rad Laboratories (US), Abcam (UK), PerkinElmer (US), QIAGEN N.V (Netherlands), and Merck KGaA (Germany), OpGen (US), Creative Bioarray (US), ZytoVision (Germany), BioCat GmbH (Germany), and Enzo Biochem (US)

Research Coverage:
The report segments the ISH market based on region (North America, Asia Pacific, Europe, and RoW), product (consumables, instruments, and software), application (Cancer diagnostics, cytology, infectious disease diagnostics, neuroscience, and immunology), and end-user (hospitals & diagnostic laboratories, academic & research institutes, pharmaceutical & biotechnology companies, and CROs).
The report also provides a comprehensive review of market drivers, challenges, and opportunities in the ISH market.

Key Benefits of Buying the Report:
The report will help the leaders/new entrants in this market with information on the closest approximations of the revenue numbers for the overall market and the sub-segments. This report will help stakeholders understand the competitive landscape and gain more insights to better position their businesses and plan suitable go-to-market strategies. The report also helps stakeholders understand the pulse of the ISH market and provides them information on key market drivers, challenges, and opportunities.

【レポートの目次】

1 INTRODUCTION 26
1.1 OBJECTIVES OF THE STUDY 26
1.2 MARKET DEFINITION 26
1.2.1 INCLUSIONS & EXCLUSIONS 26
1.3 MARKET SCOPE 27
1.3.1 MARKETS COVERED 27
1.3.2 YEARS CONSIDERED FOR THE STUDY 27
1.4 CURRENCY 28
1.5 LIMITATIONS 28
1.6 STAKEHOLDERS 28
1.7 SUMMARY OF CHANGES 29
2 RESEARCH METHODOLOGY 30
2.1 RESEARCH DATA 30
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 31
FIGURE 1 BREAKDOWN OF PRIMARIES: IN SITU HYBRIDIZATION MARKET 31
2.2 MARKET DATA ESTIMATION & TRIANGULATION 32
FIGURE 2 DATA TRIANGULATION METHODOLOGY 32
2.3 MARKET ESTIMATION METHODOLOGY 33
FIGURE 3 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION) 33
FIGURE 4 IN SITU HYBRIDIZATION MARKET SIZE (USD MILLION) 33
FIGURE 5 IN SITU HYBRIDIZATION MARKET: FINAL CAGR PROJECTIONS (2020−2025) 34
FIGURE 6 IN SITU HYBRIDIZATION MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES 34
2.4 INDUSTRY INSIGHTS 35
2.5 RESEARCH ASSUMPTIONS 35
3 EXECUTIVE SUMMARY 36
FIGURE 7 IN SITU HYBRIDIZATION MARKET SHARE, BY PRODUCT, 2019 36
FIGURE 8 FLUORESCENCE IN SITU HYBRIDIZATION MARKET SHARE, BY TYPE, 2019 36
FIGURE 9 IN SITU HYBRIDIZATION MARKET, BY END USER: MARKET RANKING OF SEGMENTS, BY MARKET SIZE 37
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE IN SITU HYBRIDIZATION MARKET 38
4 PREMIUM INSIGHTS 39
4.1 IN SITU HYBRIDIZATION MARKET OVERVIEW 39
FIGURE 11 RISING FOCUS ON COMPANION DIAGNOSTICS AND INCREASING DISEASE INCIDENCE WILL FAVOR MARKET GROWTH 39
4.2 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SHARE, BY END USER AND COUNTRY (2019) 40
FIGURE 12 HOSPITAL & DIAGNOSTIC LABORATORIES SEGMENT ACCOUNTED FOR
THE LARGEST SHARE OF THE ASIA PACIFIC MARKET IN 2019 40
4.3 IN SITU HYBRIDIZATION MARKET, BY PRODUCT 41
FIGURE 13 CONSUMABLES SEGMENT WILL CONTINUE TO DOMINATE THE MARKET 41
4.4 IN SITU HYBRIDIZATION MARKET SHARE, BY TECHNOLOGY, 2020 VS. 2025 41
FIGURE 14 FLUORESCENCE IN SITU HYBRIDIZATION HOLDS THE LARGEST SHARE OF
THE MARKET, BY TECHNOLOGY 41
4.5 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2020 VS. 2025 (USD MILLION) 42
FIGURE 15 KITS & REAGENTS SEGMENT ACCOUNT FOR THE LARGEST MARKET SHARE 42
5 MARKET OVERVIEW 43
5.1 INTRODUCTION 43
5.2 MARKET DYNAMICS 43
FIGURE 16 IN SITU HYBRIDIZATION MARKET: DRIVERS, OPPORTUNITIES, AND CHALLENGES 43
5.2.1 MARKET DRIVERS 43
5.2.1.1 Increasing incidence of genetic disorders and cancer 43
5.2.1.2 Awareness about companion diagnostics 44
5.2.2 OPPORTUNITIES 44
5.2.2.1 Untapped markets in developing countries 44
5.2.3 CHALLENGES 44
5.2.3.1 Lack of skilled professionals 44
5.3 VALUE CHAIN ANALYSIS 45
FIGURE 17 VALUE CHAIN ANALYSIS OF THE IN SITU HYBRIDIZATION MARKET: RAW MATERIAL AND MANUFACTURING PHASE CONTRIBUTES MAXIMUM VALUE 45
5.4 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE IN SITU HYBRIDIZATION MARKET 46
6 IN SITU HYBRIDIZATION MARKET, BY PRODUCT 47
6.1 INTRODUCTION 48
TABLE 1 IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 48
6.2 CONSUMABLES 48
TABLE 2 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 48
TABLE 3 IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY REGION,
2018–2025 (USD MILLION) 49
TABLE 4 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 49
TABLE 5 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 49
TABLE 6 APAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 50

6.2.1 KITS & REAGENTS 50
6.2.1.1 Increasing focus on companion diagnostics has driven market demand for kits & reagents 50
TABLE 7 IN SITU HYBRIDIZATION KITS & REAGENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 50
6.2.2 PROBES 51
6.2.2.1 Preference for direct localization of DNA/RNA sequences using probes is likely to drive the market 51
TABLE 8 IN SITU HYBRIDIZATION PROBES MARKET, BY REGION,
2018–2025 (USD MILLION) 51
6.2.3 ACCESSORIES 51
TABLE 9 IN SITU HYBRIDIZATION ACCESSORIES MARKET, BY REGION,
2018–2025 (USD MILLION) 51
6.3 INSTRUMENTS 52
6.3.1 NEED FOR AUTOMATED SYSTEMS SUPPORTS MARKET GROWTH 52
TABLE 10 IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY REGION,
2018–2025 (USD MILLION) 52
TABLE 11 NORTH AMERICA: IN SITU HYBRIDIZATION INSTRUMENTS MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 52
TABLE 12 EUROPE: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 53
TABLE 13 APAC: IN SITU HYBRIDIZATION INSTRUMENTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 53
6.4 SOFTWARE 53
6.4.1 DEMAND FOR SOFTWARE IS DRIVEN BY THE NEED FOR HIGH-SPEED SAMPLE DATA ANALYSIS 53
TABLE 14 IN SITU HYBRIDIZATION SOFTWARE MARKET, BY REGION,
2018–2025 (USD MILLION) 54
TABLE 15 NORTH AMERICA: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 54
TABLE 16 EUROPE: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 54
TABLE 17 APAC: IN SITU HYBRIDIZATION SOFTWARE MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 55
7 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY 56
7.1 INTRODUCTION 57
TABLE 18 IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 57
7.2 FLUORESCENCE IN SITU HYBRIDIZATION 57
TABLE 19 FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 57
TABLE 20 FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 58
TABLE 21 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 58
TABLE 22 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 58
TABLE 23 APAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 59
7.2.1 DNA FLUORESCENCE IN SITU HYBRIDIZATION 59
7.2.1.1 Need to ensure the stability of genetic material likely to drive
the market 59
TABLE 24 DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 59
TABLE 25 NORTH AMERICA: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 60
TABLE 26 EUROPE: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 60
TABLE 27 APAC: DNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 60
7.2.2 RNA FLUORESCENCE IN SITU HYBRIDIZATION 61
7.2.2.1 Rise in biomedical research activity has supported market growth 61
TABLE 28 RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 61
TABLE 29 NORTH AMERICA: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 61
TABLE 30 EUROPE: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 62
TABLE 31 APAC: RNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 62
7.2.3 PNA FLUORESCENCE IN SITU HYBRIDIZATION 62
7.2.3.1 Increased application in infectious disease resulted in market growth 62
TABLE 32 PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 63
TABLE 33 NORTH AMERICA: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 63
TABLE 34 EUROPE: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 63
TABLE 35 APAC: PNA FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 64
7.3 CHROMOGENIC IN SITU HYBRIDIZATION 64
7.3.1 COST-EFFECTIVENESS OVER FLUORESCENCE IN SITU HYBRIDIZATION FISH SUPPORTS MARKET GROWTH 64
TABLE 36 CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 64
TABLE 37 NORTH AMERICA: CHROMOGENIC IN SITU HYBRIDIZATION MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 65
TABLE 38 EUROPE: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 65
TABLE 39 APAC: CHROMOGENIC IN SITU HYBRIDIZATION MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 65

8 IN SITU HYBRIDIZATION MARKET, BY APPLICATION 66
8.1 INTRODUCTION 67
TABLE 40 IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 67
8.2 CANCER DIAGNOSTICS 67
8.2.1 INCREASING IMPORTANCE IN COMPANION DIAGNOSTICS TO DRIVE MARKET GROWTH 67
TABLE 41 IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY REGION, 2018–2025 (USD MILLION) 67
TABLE 42 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS, BY COUNTRY, 2018–2025 (USD MILLION) 68
TABLE 43 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS,
BY COUNTRY, 2018–2025 (USD MILLION) 68
TABLE 44 APAC: IN SITU HYBRIDIZATION MARKET FOR CANCER DIAGNOSTICS,
BY COUNTRY, 2018–2025 (USD MILLION) 68
8.3 CYTOLOGY 69
8.3.1 FISH IS PREFERRED IN THE DETECTION OF CHROMOSOMAL ABNORMALITIES 69
TABLE 45 IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY REGION,
2018–2025 (USD MILLION) 69
TABLE 46 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY,
BY COUNTRY, 2018–2025 (USD MILLION) 69
TABLE 47 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY, 2018–2025 (USD MILLION) 70
TABLE 48 APAC: IN SITU HYBRIDIZATION MARKET FOR CYTOLOGY, BY COUNTRY,
2018–2025 (USD MILLION) 70
8.4 INFECTIOUS DISEASE DIAGNOSTICS 70
8.4.1 NEED FOR HIGH SENSITIVITY AND SPECIFICITY IN INFECTIOUS DIAGNOSIS IS LIKELY TO SUPPORT MARKET GROWTH 70
TABLE 49 IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY REGION, 2018–2025 (USD MILLION) 71
TABLE 50 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018–2025 (USD MILLION) 71
TABLE 51 EUROPE: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018–2025 (USD MILLION) 71
TABLE 52 APAC: IN SITU HYBRIDIZATION MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2018–2025 (USD MILLION) 72
8.5 NEUROSCIENCE 72
8.5.1 RISING BURDEN OF NEUROLOGICAL DISORDERS HAS BOOSTED OVERALL R&D ACTIVITY 72
TABLE 53 IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY REGION,
2018–2025 (USD MILLION) 72
TABLE 54 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE,
BY COUNTRY, 2018–2025 (USD MILLION) 73
TABLE 55 EUROPE: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE,
BY COUNTRY, 2018–2025 (USD MILLION) 73
TABLE 56 APAC: IN SITU HYBRIDIZATION MARKET FOR NEUROSCIENCE, BY COUNTRY, 2018–2025 (USD MILLION) 73
8.6 IMMUNOLOGY 74
8.6.1 RISING INCIDENCE OF AUTOIMMUNE DISEASES SUPPORTS MARKET GROWTH 74
TABLE 57 IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY REGION,
2018–2025 (USD MILLION) 74
TABLE 58 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY,
BY COUNTRY, 2018–2025 (USD MILLION) 74
TABLE 59 EUROPE: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2025 (USD MILLION) 75
TABLE 60 APAC: IN SITU HYBRIDIZATION MARKET FOR IMMUNOLOGY, BY COUNTRY, 2018–2025 (USD MILLION) 75
9 IN SITU HYBRIDIZATION MARKET, BY END USER 76
9.1 INTRODUCTION 77
TABLE 61 IN SITU HYBRIDIZATION MARKET, BY END USER, 2018–2025 (USD MILLION) 77
9.2 HOSPITAL & DIAGNOSTIC LABORATORIES 77
9.2.1 DEMAND FOR MOLECULAR TESTS TO DRIVE MARKET GROWTH 77
TABLE 62 IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY REGION, 2018–2025 (USD MILLION) 78
TABLE 63 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 64 EUROPE: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 78
TABLE 65 APAC: IN SITU HYBRIDIZATION MARKET FOR HOSPITAL & DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018–2025 (USD MILLION) 79
9.3 ACADEMIC & RESEARCH INSTITUTES 79
9.3.1 INCREASING RESEARCH ON CHROMOSOMAL ABNORMALITIES WILL SUPPORT MARKET GROWTH 79
TABLE 66 IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION) 79
TABLE 67 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 68 EUROPE: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 80
TABLE 69 APAC: IN SITU HYBRIDIZATION MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION) 80
9.4 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 81
9.4.1 NEED TO DEVELOP PRECISION TREATMENTS DRIVES DEMAND FOR IN SITU HYBRIDIZATION 81
TABLE 70 IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION) 81
TABLE 71 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 81
TABLE 72 EUROPE: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 82
TABLE 73 APAC: IN SITU HYBRIDIZATION MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION) 82

9.5 CONTRACT RESEARCH ORGANIZATIONS 82
9.5.1 INCREASING OUTSOURCING OF RESEARCH ACTIVITIES TO SUPPORT MARKET GROWTH 82
TABLE 74 IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION) 83
TABLE 75 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 76 EUROPE: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 83
TABLE 77 APAC: IN SITU HYBRIDIZATION MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION) 84
10 IN SITU HYBRIDIZATION MARKET, BY REGION 85
10.1 INTRODUCTION 86
FIGURE 18 IN SITU HYBRIDIZATION MARKET SNAPSHOT 86
TABLE 78 IN SITU HYBRIDIZATION MARKET, BY REGION, 2018–2025 (USD MILLION) 86
10.2 NORTH AMERICA 87
FIGURE 19 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET SNAPSHOT 87
TABLE 79 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 88
TABLE 80 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 88
TABLE 81 NORTH AMERICA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2018–2025 (USD MILLION) 88
TABLE 82 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 89
TABLE 83 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 89
TABLE 84 NORTH AMERICA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2018–2025(USD MILLION) 89
TABLE 85 NORTH AMERICA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 90
10.2.1 US 90
10.2.1.1 Government funding for life science research drives the market growth in the US 90
TABLE 86 US: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 90
TABLE 87 US: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 91
TABLE 88 US: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 91
TABLE 89 US: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 91
TABLE 90 US: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 92
TABLE 91 US: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 92

10.2.2 CANADA 92
10.2.2.1 Investments by the Canadian government and non-profit organizations for innovation are likely to boost the market 92
TABLE 92 CANADA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 93
TABLE 93 CANADA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 93
TABLE 94 CANADA: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 93
TABLE 95 CANADA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 94
TABLE 96 CANADA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 94
TABLE 97 CANADA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 94
10.3 EUROPE 95
TABLE 98 EUROPE: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 95
TABLE 99 EUROPE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 95
TABLE 100 EUROPE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 95
TABLE 101 EUROPE: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 96
TABLE 102 EUROPE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 96
TABLE 103 EUROPE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 96
TABLE 104 EUROPE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 97
10.3.1 GERMANY 97
10.3.1.1 Germany accounted for the largest share of the European market 97
TABLE 105 GERMANY: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 97
TABLE 106 GERMANY: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 107 GERMANY: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 98
TABLE 108 GERMANY: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 98
TABLE 109 GERMANY: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE, 2018–2025 (USD MILLION) 99
TABLE 110 GERMANY: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 99
10.3.2 FRANCE 99
10.3.2.1 Increased investments in proteomics and genomics are likely to fuel the growth of ISH technology 99
TABLE 111 FRANCE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 100
TABLE 112 FRANCE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 100
TABLE 113 FRANCE: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 100
TABLE 114 FRANCE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 101
TABLE 115 FRANCE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 101
TABLE 116 FRANCE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 101
10.3.3 UK 102
10.3.3.1 Increasing focus on cancer research in the UK is a key market growth driver 102
TABLE 117 UK: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 102
TABLE 118 UK: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 102
TABLE 119 UK: IN SITU HYBRIDIZATION MARKET, BY END USER, 2018–2025 (USD MILLION) 103
TABLE 120 UK: IN SITU HYBRIDIZATION MARKET, BY PRODUCT, 2018–2025 (USD MILLION) 103
TABLE 121 UK: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 103
TABLE 122 UK: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 104
10.3.4 REST OF EUROPE 104
TABLE 123 ROE: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 104
TABLE 124 ROE: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 104
TABLE 125 ROE: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 105
TABLE 126 ROE: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 105
TABLE 127 ROE: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 105
TABLE 128 ROE: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 106
10.4 ASIA PACIFIC 107
FIGURE 20 ASIA PACIFIC: IN SITU HYBRIDIZATION MARKET SNAPSHOT 107
TABLE 129 APAC: IN SITU HYBRIDIZATION MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 108
TABLE 130 APAC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 108
TABLE 131 APAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 108
TABLE 132 APAC: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 109
TABLE 133 APAC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 109
TABLE 134 APAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 109
TABLE 135 APAC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 110
10.4.1 JAPAN 110
10.4.1.1 Focus on personalized diagnostics products to support market growth in Japan 110
TABLE 136 JAPAN: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 110
TABLE 137 JAPAN: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 111
TABLE 138 JAPAN: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 111
TABLE 139 JAPAN: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 111
TABLE 140 JAPAN: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 112
TABLE 141 JAPAN: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 112
10.4.2 CHINA 112
10.4.2.1 China forms the fastest-growing market in the APAC 112
TABLE 142 CHINA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 113
TABLE 143 CHINA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 113
TABLE 144 CHINA: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 113
TABLE 145 CHINA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 114
TABLE 146 CHINA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 114
TABLE 147 CHINA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 114
10.4.3 INDIA 115
10.4.3.1 Collaborations between hospitals and diagnostics labs will propel market growth in India 115
TABLE 148 INDIA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 115
TABLE 149 INDIA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 115
TABLE 150 INDIA: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 116
TABLE 151 INDIA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 116
TABLE 152 INDIA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 116
TABLE 153 INDIA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 117
10.4.4 REST OF ASIA PACIFIC 117
TABLE 154 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 117
TABLE 155 ROAPAC: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 117
TABLE 156 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 118
TABLE 157 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 118
TABLE 158 ROAPAC: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 159 ROAPAC: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 119
10.5 REST OF THE WORLD 119
TABLE 160 ROW: IN SITU HYBRIDIZATION MARKET, BY REGION,
2018–2025 (USD MILLION) 119
TABLE 161 ROW: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 119
TABLE 162 ROW: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 120
TABLE 163 ROW: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 120
TABLE 164 ROW: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 120
TABLE 165 ROW: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 121
TABLE 166 ROW: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 121
10.5.1 LATIN AMERICA 121
10.5.1.1 Growing cancer screening programs will propel market growth in Latin America 121
TABLE 167 LATAM: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 122
TABLE 168 LATAM: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 122
TABLE 169 LATAM: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 122
TABLE 170 LATAM: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 123
TABLE 171 LATAM: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 123
TABLE 172 LATAM: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 123
10.5.2 MIDDLE EAST & AFRICA 124
10.5.2.1 Infrastructural development is expected to contribute to the growth of the MEA market 124
TABLE 173 MEA: IN SITU HYBRIDIZATION MARKET, BY TECHNOLOGY,
2018–2025 (USD MILLION) 124
TABLE 174 MEA: FLUORESCENCE IN SITU HYBRIDIZATION MARKET, BY TYPE,
2018–2025 (USD MILLION) 124
TABLE 175 MEA: IN SITU HYBRIDIZATION MARKET, BY END USER,
2018–2025 (USD MILLION) 124
TABLE 176 MEA: IN SITU HYBRIDIZATION MARKET, BY PRODUCT,
2018–2025 (USD MILLION) 125
TABLE 177 MEA: IN SITU HYBRIDIZATION CONSUMABLES MARKET, BY TYPE,
2018–2025 (USD MILLION) 125
TABLE 178 MEA: IN SITU HYBRIDIZATION MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 125
11 COMPETITIVE LANDSCAPE 126
11.1 INTRODUCTION 126
11.2 MARKET RANKING ANALYSIS 126
FIGURE 21 COMPANY RANKING IN THE IN SITU HYBRIDIZATION MARKET, 2019 126
11.3 MARKET EVALUATION FRAMEWORK 127
TABLE 179 MARKET EVALUATION FRAMEWORK: AGREEMENT & PRODUCT LAUNCH—
THE MAJOR STRATEGY ADOPTED BY PLAYERS 127
11.4 COMPETITIVE SCENARIO 127
11.4.1 KEY PRODUCT LAUNCHES 127
11.4.2 KEY COLLABORATIONS & AGREEMENTS 127
11.4.3 KEY EXPANSIONS 127
12 COMPANY EVALUATION MATRIX AND COMPANY PROFILES 128
12.1 OVERVIEW 128
12.2 IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX 128
12.2.1 STARS 128
12.2.2 EMERGING LEADERS 128
12.2.3 PERVASIVE COMPANIES 128
12.2.4 EMERGING COMPANIES 128
FIGURE 22 GLOBAL IN SITU HYBRIDIZATION MARKET: COMPANY EVALUATION MATRIX, 2019 129
12.3 COMPANY PROFILES 130
12.3.1 ABBOTT LABORATORIES 130
FIGURE 23 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 130
12.3.2 F. HOFFMANN-LA ROCHE 132
FIGURE 24 F. HOFFMANN-LA ROCHE AG: COMPANY SNAPSHOT (2019) 132
12.3.3 AGILENT TECHNOLOGIES 134
FIGURE 25 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT (2019) 134
12.3.4 THERMO FISHER SCIENTIFIC 136
FIGURE 26 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2019) 136
12.3.5 BIO-TECHNE CORPORATION 138
FIGURE 27 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2019) 138
12.3.6 QIAGEN N.V. 140
FIGURE 28 QIAGEN N.V.: COMPANY SNAPSHOT (2019) 140
12.3.7 DANAHER CORPORATION 142
FIGURE 29 DANAHER CORPORATION: COMPANY SNAPSHOT (2019) 142
12.3.8 PERKINELMER 144
FIGURE 30 PERKINELMER: COMPANY SNAPSHOT (2019) 144
12.3.9 ENZO BIOCHEM 146
FIGURE 31 ENZO BIOCHEM: COMPANY SNAPSHOT (2019) 146
12.3.10 BIO-RAD LABORATORIES 147
FIGURE 32 BIO-RAD LABORATORIES: COMPANY SNAPSHOT (2019) 147
12.3.11 MERCK KGAA 148
FIGURE 33 MERCK KGAA: COMPANY SNAPSHOT (2019) 148
12.3.12 ABNOVA CORPORATION 150
12.3.13 BIOGENEX LABORATORIES 151
12.3.14 BIOCARE MEDICAL 153
12.3.15 OPGEN 154
FIGURE 34 OPGEN: COMPANY SNAPSHOT (2019) 154
12.3.16 BIO SB 155
12.3.17 GENEMED BIOTECHNOLOGIES 156
12.3.18 ABCAM 157
FIGURE 35 ABCAM: COMPANY SNAPSHOT (2019) 157
12.3.19 CREATIVE BIOARRAY 159
12.3.20 BIOCAT GMBH 160
12.3.21 ZYTOVISION 161
13 APPENDIX 163
13.1 DISCUSSION GUIDE 163
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 166
13.3 AVAILABLE CUSTOMIZATIONS 168
13.4 RELATED REPORTS 168
13.5 AUTHOR DETAILS 169



★調査レポート[In situハイブリダイゼーション(ISH)の世界市場予測(〜2025):製品別(消耗品(キット、プローブ)、ソフトウェア)、技術別(FISH(DNA、RNA)、CISH)、用途別(癌、感染症)、エンドユーザー別(診断ラボ、研究所、CRO)、地域別] ( In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025 / BT 3649) 販売に関する免責事項
[In situハイブリダイゼーション(ISH)の世界市場予測(〜2025):製品別(消耗品(キット、プローブ)、ソフトウェア)、技術別(FISH(DNA、RNA)、CISH)、用途別(癌、感染症)、エンドユーザー別(診断ラボ、研究所、CRO)、地域別] ( In Situ Hybridization (ISH) Market by Product (Consumables (Kits, Probes) Software), Technology (FISH (DNA, RNA), CISH), Application (Cancer, Infectious Disease), and End User (Diagnostic Labs, Research Institutes, CROs), Region - Global Forecast to 2025 / BT 3649) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆